As part of our ongoing series focussing on available medicines in Australia, we have added a product review of Anifrolumab for adult patients with moderate-to-severe, active systemic lupus erythematosus.
This review discusses pharmacological properties, drug interactions and major studies featuring Anifrolumab. It also provides commentary and recommendations from Professor Paul Bird a clinical rheumatologist, and chief medical officer at Emeritus Clinical Research in Sydney.
Please login below to download this issue (PDF)